Biological Implications of the Overlapping Phenomenon Between Childhood Schizophrenia and Autism Spectrum Disorders-Heterogeneity Approach Rather Than Diagnostic Boundary

Sponsor
National Taiwan University Hospital (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT06063525
Collaborator
(none)
230
118.9

Study Details

Study Description

Brief Summary

Complex diseases such as schizophrenia and autism are heterogeneous in clinical presentation and etiology. This high heterogeneity constitutes the challenges for the clinical diagnosis and etiological research, resulting in that the majority of research findings cannot be replicated in the independent samples. For the high comorbid rate between the diagnoses of schizophrenia and autism spectrum disorders (ASD), and the shared neurocognitive deficits, genetic risks, and biological markers between the two disorders, a heterogeneity approach may probably be more promising than to arbitrarily split the two diagnostic categories apart or lump them together for etiological research. In schizophrenia, patients with a very early onset of disease and with preceding neurodevelopmental conditions may imply a different underlying etiology from those with typical onset and without neurodevelopmental conditions. Echoing the evidence that in early onset Parkinson's disease, PARK2 (encoding parkin protein) mutations are successfully reported to be as frequent as 49% with an autosomal-recessive mode of inheritance , representing a specific disease entity of Parkinson's disease. Therefore, it is critical to characterize the clinical phenotypes for this subpopulation of very early onset patients, including their clinical manifestation, disease course, and treatment response, as well as early developmental history and morphological characteristics. These may establish an important base for investigating the etiology and providing adequate clinical care for the heterogeneous syndrome of schizophrenia

Condition or Disease Intervention/Treatment Phase
  • Other: Structural anatomy

Study Design

Study Type:
Observational
Anticipated Enrollment :
230 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Biological Implications of the Overlapping Phenomenon Between Childhood Schizophrenia and Autism Spectrum Disorders-Heterogeneity Approach Rather Than Diagnostic Boundary
Actual Study Start Date :
Feb 2, 2015
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
childhood onset schizophrenia (COS)

diagnosis of schizophrenia under the age of 13 years.

Other: Structural anatomy
images acquired with 3T MRI system with 32 channel head coil

schizophrenia (SZ)

patients with schizophrenia with and age of onset later than 13 years

Other: Structural anatomy
images acquired with 3T MRI system with 32 channel head coil

autism spectrum disorder (ASD)

dual diagnosis of schizophrenia and ASD, including SZ with ASD, COS with ASD

Other: Structural anatomy
images acquired with 3T MRI system with 32 channel head coil

Outcome Measures

Primary Outcome Measures

  1. Positive and Negative Syndrome Scale PANSS [3 years]

    33 item scale composed of 7 positive scale, 7 negative scale, 16 general psychopathology, and 3 aggression risk profile. Range from 0 to 7, higher the score, more severe the symptoms are.

  2. Autism Diagnostic Observation Schedule [3 years.]

    interview with subjects. range from 0 to 8, higher the score, worse the autistic symptoms.

  3. Physical anomalies and craniofacial features [3 years]

    41 qualitative items were used to examine the presence or absence of morphological anomalies and magnitude of anomalies. Minor physical anomalies were rated from 0 to 83, higher the score, greater the anomalies.

  4. Brain structural anatomy with MRI scan [3 years]

    3 Tesla MRI with a 32-channel head coil was used to collect brain imaging of cortical thickness, cortical volume, white matter volume, gyrification. The MRI structural images will be analyzed using FreeSurfer image analysis suite.

Eligibility Criteria

Criteria

Ages Eligible for Study:
15 Years to 59 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • SZ group: schizophrenia onset earlier than 12 years old

  • COS group: schizophrenia onset later than 12 years old

  • ASD group: diagnosed with autism spectrum disorder without schizophrenia

  • Dual group: diagnosed with ASD and SZ

Exclusion Criteria:
  • congenital disease

  • major physical diseases

  • neurodegenerative disorder

  • chromosomal aberration

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • National Taiwan University Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT06063525
Other Study ID Numbers:
  • 201412165RINB
First Posted:
Oct 2, 2023
Last Update Posted:
Oct 2, 2023
Last Verified:
Jan 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 2, 2023